- Home
- AEON vs ADIL Comparison
AEON vs ADIL Comparison
Compare AEON & ADIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AEON | ADIL |
|---|---|---|
| Founded | N/A | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.0M | 11.4M |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | AEON | ADIL |
|---|---|---|
| Price | $0.23 | $3.22 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 4 |
| Target Price | $1.82 | ★ $8.33 |
| AVG Volume (30 Days) | ★ 1.3M | 39.2K |
| Earning Date | 11-13-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.18 | $0.13 |
| 52 Week High | $1.45 | $9.90 |
Technical Indicators
Market Signals| Indicator | AEON | ADIL |
|---|---|---|
| Relative Strength Index (RSI) | 40.82 | 29.42 |
| Support Level | $0.18 | $2.38 |
| Resistance Level | $0.33 | $4.94 |
| Average True Range (ATR) | 0.03 | 0.42 |
| MACD | -0.00 | -0.10 |
| Stochastic Oscillator | 8.72 | 1.86 |
Price Performance
Historical ComparisonAbout AEON AEON Biopharma Inc.
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.
About ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder. The company operates as one operating segment with a focus on drug development for addiction and related disorders.